Nuvalent, Inc. (NUVL) DCF Valuation

NUVALENT, Inc. (NUVL) Valoración de DCF

US | Healthcare | Biotechnology | NASDAQ
Nuvalent, Inc. (NUVL) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Nuvalent, Inc. (NUVL) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¡Mejore sus estrategias de inversión con la calculadora DCF de NUValent, Inc. (NUVL)! Explore datos financieros reales, ajuste las predicciones y gastos de crecimiento, y observe instantáneamente cómo estas modificaciones afectan el valor intrínseco de Nuvalent, Inc. (NUVL).


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -1.5 2.3 -45.8 -86.1 -149.5 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation 10.4 16.9 .2 -.4 .0 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -11.8 -14.6 -46.0 -85.7 -149.5 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 3.0 10.3 288.1 472.2 719.9 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable .7 1.3 2.9 7.2 9.3 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -11.8 -14.6 -46.0 -76.8 -149.5 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -.7 2.9 -44.2 -72.9 -147.4 -9.3 .0 .0 .0 .0
WACC, % 10.72 10.72 10.72 10.72 10.72 10.72 10.72 10.72 10.72 10.72
PV UFCF
SUM PV UFCF -8.4
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -8
Net Debt -335
Equity Value 327
Diluted Shares Outstanding, MM 58
Equity Value Per Share 5.62

What You Will Get

  • Real Nuvalent Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
  • Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
  • Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Nuvalent’s fair value.
  • Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
  • Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.

Key Features

  • Comprehensive DCF Model: Features detailed unlevered and levered DCF valuation frameworks tailored for Nuvalent, Inc. (NUVL).
  • WACC Tool: Pre-configured Weighted Average Cost of Capital calculator with adjustable parameters.
  • Customizable Forecast Inputs: Adjust growth projections, capital investments, and discount rates as needed.
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency metrics specific to Nuvalent, Inc. (NUVL).
  • Visual Dashboard and Graphs: Graphical representations that highlight essential valuation indicators for straightforward analysis.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Nuvalent, Inc. (NUVL) data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Nuvalent, Inc. (NUVL)’s intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose This Calculator for Nuvalent, Inc. (NUVL)?

  • Designed for Experts: A sophisticated tool utilized by industry analysts, CFOs, and strategic consultants.
  • Accurate Financial Data: Nuvalent’s historical and projected financials are preloaded for precision.
  • Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
  • Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential financial metrics.
  • User-Friendly: Step-by-step guidance ensures a smooth user experience.

Who Should Use Nuvalent, Inc. (NUVL)?

  • Biotech Students: Explore drug development processes and apply them to real-world case studies.
  • Researchers: Integrate innovative models into your studies or clinical trials.
  • Investors: Evaluate your investment strategies and analyze market performance for Nuvalent, Inc. (NUVL).
  • Pharmaceutical Analysts: Enhance your analysis with a tailored, comprehensive model for drug valuation.
  • Healthcare Entrepreneurs: Understand how biotech firms like Nuvalent, Inc. (NUVL) are assessed in the market.

What the Template Contains

  • Historical Data: Includes Nuvalent, Inc.’s (NUVL) past financials and baseline forecasts.
  • DCF and Levered DCF Models: Detailed templates to calculate Nuvalent, Inc.’s (NUVL) intrinsic value.
  • WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital for Nuvalent, Inc. (NUVL).
  • Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions for Nuvalent, Inc. (NUVL).
  • Quarterly and Annual Statements: A complete breakdown of Nuvalent, Inc.’s (NUVL) financials.
  • Interactive Dashboard: Visualize valuation results and projections dynamically for Nuvalent, Inc. (NUVL).

No products were found matching.